This hallmark achievement is significant as it helped address the unmet medical need to minimize gadolinium (Gd) exposure per MRI procedure without compromising image quality.
VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL is a macrocyclic gadolinium-based contrast agent (GBCA) that offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) vs. a macrocyclic GBCA at a dose of 0.1 mmol/kg of other similar contrast media for approved indications in the U.S.
Ryan Murtagh, MD, Chief of Neuroradiology at Tampa General Hospital and Tampa General Hospital Imaging, said, "As one of the first facilities to adopt VUEWAY (gadopiclenol) solution for injection back in February 2023, we are honored to have administered the one-millionth dose here at Tampa General. VUEWAY injection, with its FDA-labeled dose at half the gadolinium of what other approved macrocyclic agents require in similar indications, has proven to be a game-changer in our practice. It underscores our commitment to advancing patient care by embracing innovation."
With its lower dose of the active ingredient, Gd, VUEWAY injection is a desirable choice for all MRI patients especially those who may require multiple MRI scans with contrast throughout their care.
"We at Bracco are delighted with the rapid adoption of this exciting product (VUEWAY injection) and sincerely thank the imaging community for embracing this approach to patient care," said Cosimo De Pinto, Senior Vice President of Sales and Marketing at Bracco Diagnostics Inc.
"Our singular focus at Bracco is about improving patient lives and offering VUEWAY injection is a perfect example of this commitment. We're proud to support our customers by providing the highest level of service, science, and breadth of innovative products," concluded De Pinto.
VUEWAY® (gadopiclenol) solution for injection:
Indications
VUEWAY injection is indicated in adults and children aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:
the central nervous system (brain, spine, and associated tissues),
the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
About Bracco Imaging:
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry.
For more information please visit, www.bracco.com
